Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

Investors may be wary of Laurus Labs Limited as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 1.32800
forwardPE 60.56433
debtToEquity 46.36900
earningsGrowth 0.19400
revenueGrowth 0.05300
grossMargins 0.58468
operatingMargins 0.21624
trailingEps 16.38000
forwardEps 23.99267

The current ratio for LAURUSLABS is 1.328, indicating that the company can service its short-term debt using available cash and assets. This suggests LAURUSLABS has strong liquidity, with more than enough resources to meet its immediate financial commitments.
Laurus Labs Limited's forward PE is elevated, which could constrain price appreciation and lead to a correction. Investors should consider this parameter in conjunction with other fundamentals to fully assess whether the stock is priced fairly.
With positive gross and operating margins, LAURUSLABS demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
LAURUSLABS's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that LAURUSLABS is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

The price of LAURUSLABS has surpassed the higher end of projections, showing strong upward momentum. However, with limited space for further increases, the stock may be due for a correction or stabilization in the near term.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


The recent buy bias from analysts suggests LAURUSLABS is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, LAURUSLABS appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.